Table 1.
Baseline characteristics and outcomes of acute stroke patients treated with intravenous thrombolysis according to the Safe Implementation of Treatments in Stroke protocol in Greece.
| Variable | n = 523 |
|---|---|
| Baseline characteristics | |
| Age (mean ± SD), years | 62.4 ± 12.7 |
| Females (%) | 34.6% |
| Admission NIHSS (median, IQR) | 11 (7–17) |
| Hypertension (%) | 60.0% |
| Diabetes (%) | 19.3% |
| Hyperlipidemia (%) | 36.6% |
| Current smoking (%) | 33.1% |
| Previous stroke (%) | 11.4% |
| Atrial fibrillation (%) | 15.3% |
| Congestive heart failure (%) | 3.3% |
| Antiplatelet pretreatment (%) | 27.8% |
| Antidiabetic pretreatment (%) | 12.5% |
| Antihypertensive pretreatment (%) | 52.6% |
| Statin pretreatment (%) | 24.9% |
| Admission SBP baseline (mean ± SD), mmHg | 149 ± 24 |
| Admission DBP (mean ± SD), mmHg | 83 ± 13 |
| Admission serum glucose (median, IQR), mg/dl | 115 (100–144) |
| Baseline total cholesterol (mean ± SD), mg/dl | 187 ± 54 |
| Early ischemic changes in baseline CT scan (%) | 8.3% |
| Disability prior to index event (%)* | 2.5% |
| Acute ischemic stroke subtype (%) | Large artery atherosclerosis: 51.4% |
| Cardioembolism: 21.2% | |
| Small vessel disease: 9.3% | |
| Cryptogenic: 9.9% | |
| Other unusual causes: 2.9% | |
| Not available: 5.3% | |
| Times from stroke onset to treatment | |
| Onset-to-door time (min, median, IQR) | 70 (45–110) |
| Door-to-imaging time (min, median, IQR) | 30 (20–45) |
| Door-to-needle time (min, median, IQR) | 67 (50–92) |
| Onset-to-treatment time (min, median, IQR) | 150 (120–180) |
| Outcomes | |
| Any ICH (%, 95% CI) | 58/503 (11.5%, 9.0–14.6%) |
| sICH – SITS-MOST (%, 95% CI) | 3/214 (1.4%, 0.3–4.2%) |
| sICH – ECASS (%, 95% CI) | 5/214 (2.3%, 0.8–5.5%) |
| sICH – NINDS (%, 95% CI) | 7/214 (3.8%, 1.5–6.7%) |
| dNIHSS at 2 h | 3 (1–5) |
| dNIHSS at 24 h | 5 (2–8) |
| mRS at 3-months (median, IQR) | 1 (0–4)** |
| FFO (mRS: 0–1) at 3-months (%, 95% CI) | 262/471 (55.6%, 51.1–60.1%)** |
| FI (mRS: 0–2) at 3-months (%, 95% CI) | 313/471 (66.5%, 62.0–70.7%)** |
| Mortality at 3-months (%, 95% CI) | 37/471 (7.9%, 5.8–10.7%)** |
mRS score prior to stroke onset >1.
last observation carried forward; follow-up was available in 471 patients.
CI, confidence interval; CT, computed tomography; DBP, diastolic blood pressure; dNIHSS, difference in NIHSS score from baseline; ECASS, European Cooperative Acute Stroke Study; FFO, favorable functional outcome; FI, functional independence; ICH, intracerebral hemorrhage; IQR, interquartile range; mRS, modified Rankin scale score; NIHSS, National Institutes of Health Stroke Scale; NINDS, National Institute of Neurological Disorders and Stroke; SBP, systolic blood pressure; SD, standard deviation; sICH, symptomatic ICH; SITS-MOST, Safe Implementation of Treatments in Stroke Monitoring Study.